Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 45,20 € (+21,77 %). Medianen er 46,19 € (+24,43 %).
| Køb |
3 |
| Behold |
0 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
LB Pharmaceuticals appoints Dr. Susan G. Kozauer as chief medical officer
LB Pharmaceuticals has appointed Dr. Susan G. Kozauer as chief medical officer. Kozauer brings more than 20 years of experience in developing neuropsychiatric drugs, most recently serving as senior vice president and head of clinical development at Centessa Pharmaceuticals. The appointment comes ahead of the expected topline results from the Phase 3 NOVA‑2 trial of LB‑102 for schizophrenia, anticipated in the first half of 2027. Kozauer holds a degree from Cornell, an MD from George Washington University, and completed a psychiatry residency at Georgetown University Hospital. » Mere på de.investing.com
Virksomhedstal
| (EUR) | juni 2026 | |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | -84,99 t | - |
| Nettoresultat | -45,22 mio. | 947,33 % |
| EBITDA | -47,16 mio. | 965,48 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,06 mia. € |
Antal aktier | 28,68 mio. |
Højeste/laveste i 52 uger | 43,71 € - 11,64 € |
| Udbytte | Nej |
Beta | 0,42 |
P/E (PE Ratio) | -14,33 |
PEG (PEG Ratio) | -0,08 |
K/I (PB Ratio) | 3,86 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
Biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige Therapien für neuropsychiatrische Erkrankungen (z. B. Schizophrenie, bipolare Depression) entwickelt. Hauptkandidat ist LB-102, ein methyliertes Derivat von Amisulprid.
| Navn | LB Pharmaceuticals |
| CEO | Heather D. Turner |
| Websted | |
| Børsnotering | 11.09.2025 |
| Medarbejdere | 49 |
